<DOC>
	<DOCNO>NCT02920658</DOCNO>
	<brief_summary>This study evaluate effectiveness topical NAVS naphthalan treatment oral lichen planus ( OLP ) recurrent aphthous stomatitis ( RAS ) . Half participant OLP RAS receive topical NAVS naphthalan adhesive paste , half receive 0.05 % -betamethasone dipropionate adhesive paste . Our hypothesis NAVS could efficient treatment OLP RAS , effect comparable topical steroid .</brief_summary>
	<brief_title>Topical `` Non-Aromatic Very Rich Steranes '' ( NAVS ) Naphthalan Treatment Oral Mucosal Diseases</brief_title>
	<detailed_description>Non-Aromatic-Very rich Steranes ( NAVS ) naphthalan transparent , earth mineral oil prepare complex set procedure separation refine , start special oil use raw material brown naphthalane , successfully use treatment psoriasis . In order remove potentially mutagenic polycyclic aromatic hydrocarbon ( PAHs ) , liquid chromatography use . UV / VIS ( ultra violet / visible light ) spectrophotometry confirm PAHs bellow detection threshold . Additionally , precise distillation process concentrate steranes , important bioactive constituent . Since steranes contain similar chemical structure well-known bioactive substance , vitamin D3 steroid hormone , assumption NAVS effective treatment oral disease immune genesis OLP RAS . Today , topical steroid preparation consider first-line therapy many chronic immune-mediated inflammatory diseases oral mucosa . Risks short-term use topical corticosteroid clinically insignificant , long-term use recommend potential side effect , mucosal atrophy , secondary infection Candida albicans , possible systemic absorption suppression adrenal gland . Study participant adult patient Department Oral Medicine , School Dental Medicine Zagreb , clinically histologically proven OLP RAS acute stage disease.The treatment outcome OLP patient measure clinical improvement subjective symptomatic relief . The outcome RAS patient treat NAVS naphthalan betamethasone measure clinically decrease number size lesion well subjective symptomatic relief treatment period . One member team , evaluate therapeutic effect , take care allocation test control preparation . At end study , randomization code open statistically analyse . In clinical subjective domain , clinical condition , improvement rate measure compare reading , percentual reduction clinical score symptom . Since data normally distribute , method nonparametric statistic use : Wilcoxon test dependent Mann-Withney test independent sample . Baseline intergroup difference assess Mann-Withney test . For interpretation average value , median interquartile range ( IQR ) use . Fisher exact test use compare gender representation among group . Statistical analysis perform use MedCalc Software 13.0.0.0 ( Acacialaan 22 , 8400 Ostend , Belgium ) . P value low 0.05 ( p &lt; 0.05 ) consider statistically significant .</detailed_description>
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Stomatitis , Aphthous</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>OLP patient : adult patient clinically histologically proven OLP ( AlHashimi et al , 2007 ) RAS patient : acute stage disease , accord Lehner ( 1968 ) , least 2 episode per year OLP patient : young 18 year , hepatobiliary system disease , lichenoid reaction ( amalgam , drug ) lichen planus lesion contact restorative material ( Zakrzewska et al , 2005 ) , current comparative systemic local antiinflammatory treatment ( antibiotic , corticosteroid , nonsteroidal antirheumatic drug , chemotherapeutics ) ( Lo Muzio et al , 2001 ; Nolan et al , 2006 ; Rodriguez et al , 2007 ) pregnancy . RAS patient : patient young 18 year , haematological deficit ( assessed complete blood count ( CBC ) , iron ( Fe ) , vitamin B12 , hypersensitivity toothpaste oral mouth rinse solution ( assessed medical history ) ( Nolan et al , 2006 ) , pregnancy , inflammatory bowel disease ( assessed medical history ) , significant immunodeficiency , current comparative systemic topical antiinflammatory treatment ( antibiotic , corticosteroid , nonsteroidal antirheumatics , chemotherapeutics ) ( Lo Muzio et al , 2001 ; Nolan et al , 2006 ; Rodriguez et al , 2007 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>NAVS Naphthalan</keyword>
	<keyword>Betamethasone dipropionate</keyword>
	<keyword>Topical treatment</keyword>
</DOC>